Joanne M. Donovan is CMO at Edgewise Therapeutics, Inc. (EWTX). They have made 6 open-market trades across 1 company since 2023, most recently 2026-08-13.
CIK 0001644087
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EWTX | 8,625 | $321K |
| CATB | 409 | — |
| Total | $321K |
Shares reported on the most recent Form 4, priced at the 2026-08-14 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EWTX | SELL · 10b5-1 | 2026-08-12 | 2026-08-14 | $43.71 | $413K | +1.7% | +2.0% | — |
| EWTX | SELL · 10b5-1 | 2026-05-04 | 2026-05-05 | $37.88 | $2.1M | -13.1% | -2.3% | +0.8% |
| EWTX | SELL · 10b5-1 | 2026-04-01 | 2026-04-02 | $32.31 | $926K | +1.8% | -5.0% | +18.3% |
| EWTX | SELL · 10b5-1 | 2026-03-31 | 2026-03-31 | $32.12 | $1.4M | +6.0% | -3.0% | +28.2% |
| EWTX | SELL | 2026-03-27 | 2026-03-30 | $30.98 | $1.0M | +7.0% | -0.8% | +33.5% |
| EWTX | SELL | 2025-08-12 | 2025-08-14 | $13.39 | $38K | +4.4% | -2.0% | +51.4% |
| EWTX | SELL | 2025-05-02 | 2025-05-07 | $16.45 | $171K | +1.9% | +5.0% | -5.3% |
| EWTX | SELL · 10b5-1 | 2025-01-28 | 2025-01-30 | $27.63 | $691K | -9.6% | -11.8% | -43.4% |
| EWTX | SELL | 2024-09-20 | 2024-09-24 | $28.29 | $405K | +12.6% | +37.2% | +18.8% |
| EWTX | SELL | 2024-05-02 | 2024-05-03 | $18.91 | $139K | -8.4% | -9.8% | -13.2% |
| EWTX | SELL | 2023-05-02 | 2023-05-03 | $8.90 | $29K | -2.1% | +5.3% | -23.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.